Dr. Lindborg was appointed to the Board of Directors in June 2021. Dr. Lindborg is EVP and Global Head of Clinical Development at Brainstorm Cell Therapeutics. A member Brainstorm’s Executive Leadership Team, she is accountable for driving the creation of clinical development strategies from first-in-human trials through registration –framing development paths and ensuring evidence is generated as required by key constituents (scientific community, regulatory, commercial/payer). She interacts frequently with Wall Street investors, represents the company in the scientific community as well as the media and plays an active role as Brainstorm seeks business partnerships. She has core competencies in Research & Development, Executive Management, and Strategy Development.
At Eli Lilly and Company Dr. Lindborg was Head of R&D strategy, responsible for characterizing the productivity of the portfolio and driving key R&D strategy projects including the annual R&D Long-Range Plan. In this role she created seminal insights into R&D productivity by connecting individual drug program-based development decisions to portfolio risk practices, driving fundamental R&D decisions to increase the number of drug launches. Stacy was Leader of Zyprexa Product Management; responsible for R&D, Commercial, and Manufacturing plans. She was accountable for driving market share through product differentiation, Global Registration, and Launching of an injectable form of Zyprexa, working through Manufacturing Inspections and 483 citations. Zyprexa had peak sales of $4.7b.
Dr. Lindborg has a Ph.D., in Statistics from Baylor University 1996, an M.A., Statistics, Baylor University 1993 and a B.A., Psychology, Math Minor, Baylor University 1992